Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma with a variable course for which no standard treatment currently exists. This webinar can help you understand how to individualize and manage therapy for each patient.

In order to select optimal therapy, the decision-making process for management of metastatic breast cancer should involve careful consideration of the available evidence and available clinical trials and a detailed discussion with patients about the benefits and risks associated with all possible treatment strategies.

High-risk neuroblastoma has historically been and continues to be an immensely difficult disease to treat in the pediatric population. It is important to identify its pathophysiology and molecular pathology to understand the role of immunotherapy, the barriers encountered with immunotherapy, and the potential for promising breakthroughs in high-risk neuroblastoma.

Systemic therapies are critical to the treatment of muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic bladder cancer. Recent approvals and clinical trial results continue to enhance the treatment landscape in this space.

Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.

Education on de-escalation of radiation therapy for rectal cancer will highlight the most current clinical trial data and help clinicians identify which patients would be the best candidates for this new approach.

T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.